Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphangioleiomyomatosis: early-phase trial registry
6 of 11 indexed Lymphangioleiomyomatosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · 6 currently recruiting · #1,577 of 28,707 conditions by registered trial count
Lymphangioleiomyomatosis: 11 US clinical trials tracked, 6 recruiting.
Lymphangioleiomyomatosis is the subject of 11 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Heart, Lung, and Blood Institute (NHLBI), running 3 of these trials.
Enrollment posture brief
Registry condition lymphangioleiomyomatosis
OPEN 6 | RECR 55% | LATE 1 | EARLY 5 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Advanced Ovarian Carcinoma (55% recruiting · 11 trials)
Lymphangioleiomyomatosis lists 6 open slots (55% of 11 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphangioleiomyomatosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphangioleiomyomatosis is recruiting above its size-band peers.
6 of 11 indexed trials (54.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Lymphangioleiomyomatosis research.
National Heart, Lung, and Blood Institute (NHLBI) accounts for 3 of 11 trials (27.3%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Lymphangioleiomyomatosis enrolment sits around 100 participants.
Median target enrolment is 100 among the 11 trials that report a genuine target (sentinel values excluded). 5 of those (45.5%) plan for fewer than 100 participants.
-
Lymphangioleiomyomatosis splits between interventional and observational designs.
6 interventional and 5 observational studies make up this index (54.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
11 total, page 1 of 1
TSC Biosample Repository and Natural History Database
National Tuberous Sclerosis Association
NCT05676099
Study of the Disease Process of Lymphangioleiomyomatosis
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001465
Safety and Durability of Sirolimus for Treatment of LAM
University of Cincinnati
NCT02432560
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
David M. Ritter
NCT06160310
Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
National Heart, Lung, and Blood Institute (NHLBI)
NCT01799538
Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)
Columbia University
NCT06889168
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
NCT01552434
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
University of Cincinnati
NCT03150914
Feasibility of [11C]Acetate-PET in LAM and TSC
Brigham and Women's Hospital
NCT05467397
Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women
National Heart, Lung, and Blood Institute (NHLBI)
NCT00552955
A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
Novartis Pharmaceuticals
NCT01059318
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphangioleiomyomatosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphangioleiomyomatosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphangioleiomyomatosis page
11 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 6 Lymphangioleiomyomatosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Heart, Lung, and Blood Institute (NHLBI) sponsors the most Lymphangioleiomyomatosis trials on record, review their full trial history before evaluating a specific study. See National Heart, Lung, and Blood Institute (NHLBI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphangioleiomyomatosis condition card totals 11 registered trials; most-linked intervention Everolimus; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.